The top drug authority in India granted approval for Eli Lilly’s tirzepatide, the active component of their weight-loss medications Zepbound and Mounjaro, to be commercialized in the country on July 16, 2024. Just over a year after Mounjaro’s introduction, in November 2023, the FDA authorized Zepbound for the treatment of obesity. There is now a global scarcity of these medications and considerable demand for them.
There have been rumors about a new weight loss injection being offered in India as of August 2024. Usually, these injections include drugs that regulate hunger, change metabolic processes, or change how fat is absorbed in order to aid with weight control. GLP-1 receptor agonists, become more and more popular due to their success in helping people lose weight in recent years. These medications are also becoming more widely accessible.
Should this novel injection have resemblance to current extant therapies, it may constitute a sophisticated choice for those encountering difficulties with weight regulation. Before beginning any new medication, it’s crucial to take into account many elements, including the drug’s efficacy, safety record, cost, and accessibility.
To ensure you have the most up-to-date and accurate information possible, seek updates from reputable news sources and medical organizations, or speak with a healthcare practitioner about any recent developments or particular medicine names.
READ MORE : How to loose Belly fat in 4 weeks : Most effective ways
Pratap 